Euromedia24 on Play Store Euromedia24 on App Sore
BNB

$870.47

BTC

$113082

ADA

$0.868816

ETH

$4608.63

SOL

$213.76

31 °

Yerevan

20 °

Moscow

45 °

Dubai

20 °

London

26 °

Beijing

23 °

Brussels

16 °

Rome

23 °

Madrid

BNB

$870.47

BTC

$113082

ADA

$0.868816

ETH

$4608.63

SOL

$213.76

31 °

Yerevan

20 °

Moscow

45 °

Dubai

20 °

London

26 °

Beijing

23 °

Brussels

16 °

Rome

23 °

Madrid

The cause of aggressive pancreatic cancer has been revealed


Pre-pancreatic cells can effectively cope with stress and inflammation, survive and develop in aggressive tumors. This conclusion was scientists from the University of California, San Diego. The results of the study were published in Cell Reports.

Stat3, known as a protein participating in a mobile stress response, plays an important role in this process. Previous studies have shown that it helps cells adapt and become resilient therapy, but its action mechanism remains incomprehensible. The researchers have now shown that Stat3 activates the ITGB3 special gene, which stimulates the growth of the tumor and accelerates its development.

Attempts on mice have shown that even chemotherapy that causes additional stress in cells, strengthens ITGB3 activation through Stat3. This can explain why some tumors become resistant to treatment. When this path was artificially blocked, the growth of the tumor in rodents slowed significantly.

Moreover, the researchers found that Stat3 regulates a whole group of genes related to the mobile stress response. Scientists have called it a signature of Stres. This genetic marker allows us to predict exactly which cells will develop towards malecrasion and how aggressive will be tumor.

According to the authors of one of the authors of the study, Professor David Cheresh, this discovery opens the way to the early diagnosis and new personalized treatment methods. Stress signature can help detect cancer in its earliest stages, symptoms to emerge much, and predict the disease course.

Moreover, the team is already testing molecules that prevent the activation of ITGB3 by Stat3. This approach is potentially applicable not only in the case of pancreatic cancer, but also for other tumors, including lungs, breast and skin cancer.

Translation of: Euromedia24.com